Cash/Burn From SEC Filing For Period: 

Q1 '20



Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats.



Burn Rate


Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

NanoFlu vaccine


BLA: Preparing Submission


RSV Vaccine

RSV - Infants Via Maternal Immunization

Phase 3 Topline Data/ FDA Recommends Additional Studies


RSV Vaccine

RSV - Older Adults

Phase 2

Matrix-M (with Serum Institute of India)

Malaria Vaccine

Phase 2b (Top-line Data)

H2 2020


COVID-19 Vaccine

Phase 2 (Data)


RSV Vaccine

RSV - Pediatrics

Phase 1

Recent Posts

See What The Community Is Saying - Click To See Full Post

NVAX - NVX-CoV2373 Phase 1 Dat...

Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate. Scientific Summary: Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax’ COVID-19 vaccine across...

Will the current Coronavirus b...

As we started to look at NVAX, one of the recent stocks whose Coronavirus vaccine work has created some hype, we looked deeper into this question. See what we learned about influenza and SARS in our a...

NVAX COVID-19 Vaccine selected...

Novavax was selected to participate in Operation Warp Speed (OWS), a U.S governmental program that aims to begin delivering millions of doses of a COVID-19 vaccine in 2021. Novavax was rewarded $1.6 m...

Coronavirus - As the worldwide...

We have stayed out of stock trades of companies whose stock has moved directly related to new vaccine and therapeutic activities related to Coronavirus because we try to stay out of hype trades. We ar...

Why didn' NVAX move up more on...

We are surprised that NVAX isn't up more today (now up around 15% and market overall up around 1/2 of that) on positive phase 3 data for its flu vaccine candidate. Thought the market would read that ...

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon